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Abstract
Purpose To evaluate the 1-year results of using triamcin-
olone acetonide (TA) in pars plana vitrectomy (PPV).
Design Multicenter prospective controlled clinical trial.
Methods SETTING and STUDY POPULATION: the study
population comprised 774 eyes from patients treated at
eight Japanese hospitals, among which 391 eyes underwent
TA-assisted PPV and 383 control eyes underwent conven-
tional PPV. The patients were assigned to the two groups
using a single-blind quasi-randomization approach within
the participating clinical centers. INTERVENTION: intra-
operative use of TA to aid visualization of the vitreous.
MAIN OUTCOME MEASURES: changes of visual acuity,
post-operative complications (including additional surgery),
and adverse events occurring within 1 year of the operation
were compared between the TA-PPV group and the con-
ventional PPV group.
Results The visual acuity improved over time, and no sig-
nificant differences were found between the two groups
(log-rank versus TA, P=0.98 for improvement, P=0.26 for
deterioration). The logistic regression model also showed
that the intra-operative use of TA was not a significant
factor for the improvement of visual acuity [P=0.91, odds
ratio (OR)=1.10, 95% confidence interval (95%CI)=
0.860–1.183)] after adjustments for age, gender, and
diagnosis. Intra-operative TA was not a significant factor
for the need for additional surgery (log-rank test P=0.45,
logistic regression test P=0.35, OR=1.23, 95%CI=0.797–
1.911]. No serious adverse events related to surgery were
observed.
Conclusions This 1-year follow-up study of a controlled
clinical trial showed that TA-assisted PPV had neither a
positive nor a negative effect on visual acuity, the incidence
of additional surgeries, or adverse events compared with
conventional PPV.
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Recently, vitrectomy has been used to treat various
vitreoretinal diseases. It still remains a demanding proce-
dure requiring a skilled and experienced surgeon, despite
advances in surgical instrumentation and techniques. One
major difficulty with this procedure is the transparency of
the vitreous. Intra-operative triamcinolone acetonide (TA)
has been used to address this problem, as it can be injected
into the vitreous to visualize the posterior hyaloid or the
internal limiting membrane (ILM) [1, 2]. Several previous
reports have demonstrated the usefulness of TA as an
adjunct to pars plana vitrectomy (PPV) [3–13]. Although
their findings supported the use of TA-assisted PPV, these
studies involved relatively small numbers of eyes and were
not randomized. In addition, more recent reports on the use
of intravitreous TA in patients not undergoing vitrectomy
raised concerns about the risks of elevated intra-ocular
pressure (IOP) [14–19].
We therefore undertook a multicenter prospective con-
trolled study of TA-assisted pars plana vitrectomy (PPV).
Considering the enduring nature of the effect of PPV on
ocular tissue, it is important to investigate the long-term
results in order to evaluate TA-assisted PPV. Moreover, the
crucial issue of the effects on patients’ vision must be
explored before TA-assisted PPV can be recommended.
The current report presents the 1-year results of the use of
TA in PPV, and evaluates the procedure in light of the
aforementioned issues.
Methods
Study design, randomization and sample size
The prospective controlled clinical trial took place at eight
hospitals in Japan as previously described (see Acknowl-
edgements below) [13].
The patients were assigned to the two groups using a
single-blindquasi-randomization approach within thepartici-
patingclinical centers. Ourpreliminary study showed that the
most important factor influencing the surgical outcome was
not the nature of the disease for which PPV was used, but
rather the hospital in which the surgery was performed (data
not shown). To minimize this bias, equal numbers of patients
from each hospital were assigned to each of the study groups.
Thus, the patients were assigned by a single-blind quasi-
randomization within the participating clinical centers.
Briefly, after the patients passed the inclusion/exclusion
criteria and gave consent for the study, they were numbered
serially at each hospital, and alternate numbers were assigned
to the TA-assisted and conventional PPV groups, respective-
ly, as previously described [13]. Data analysis was per-
formed by an intent-to-treat analysis method. To conceal the
allocations at the participating hospitals, the surgeons were
not informed of the group to which a patient had been
assigned until immediately before surgery.
This is the second report of controlled clinical trial of
intraocular TA in PPV. Primary outcome was whether the use
of TA might reduce the incidence of intraoperative complica-
tions. The sample size was determined based upon our
preliminary study, and the method has been described
elsewhere [13]. Briefly, the incidence of intraoperative retinal
breaks was found to be approximately 15% in the participat-
ing hospitals. The sample size calculation was based on our
pilot study data, and was aimed to detect a difference in short-
term postoperative complications as reported previously [13]
Eligibility criteria and surgery
Institutional review board (IRB)/ethics committee approval
was obtained from all of the participating clinical establish-
ments,suchthatall patientsundergoingPPVatthese hospitals
were eligible to enroll in the study. Each patient was fully
informed about the nature of the treatment, and provided
written consent. The following groups were excluded: (1)
patients with diagnoses that included macular holes; patients
with uveitis, (2) patients with phakic lenses, (3) patients who
were known to be steroid responders, to have glaucoma, or to
have apparent infectious endophthalmitis, and (4) patients
who were undergoing a second PPV. For ethical reasons, if at
the time of surgery a surgeon felt that TA was necessary to
achieve a successful PPV outcome, it was included in the
procedure; for the purposes of the intent-to-treat analysis,
thesecaseswereincludedwithintheconventionalPPVgroup.
The details of the surgical protocols varied between the
hospitals, but the basic procedure was similar. PPV was per-
formed according to a previously reported methodology,
either with or without the use of a TA suspension prepared as
describedelsewhere[2, 13]. The recording of the operations,
control of surgical quality, use of antibiotics, and termina-
tion of the study have been described elsewhere [13].
During the follow-up period, additional surgeries were
performed at each hospital as and when they were needed.
For example, filtering surgeries were performed when the
intra-ocular pressure (IOP) remained at an uncontrollably
high level (25 mmHg or greater) even with full medication.
Full medication included the use of all latanoprost, beta-
blocker, and dorzolamide hydrochloride eyedrops and acet-
azolamide medicine.
Data collection and documentation were performed as
previously described [13]. For the purposes of this study,
the adverse events related to surgery were defined as
follows: retinal breaks, macular pucker, retinal fibrous
membrane formation, retinal detachment, vitreous hemor-
rhage (VH), rubeosis iridis, optic-disc damage, corneal
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related to surgery were defined as follows: infectious
endophthalmitis, retinal degeneration, unexplained optic-
disc damage, and unexplained deterioration of vision.
Masking and outcome assessment
The study records were collected by the principal investi-
gator (TS) up until November 2006. After checking the
records for harmful events, the data were sent to the
controllers (YN) at Kyushu University. The remaining
investigators were not permitted access to any information
on the outcomes before completion of the analysis. Visual
acuity was measured by ophthalmic technicians using the
Snellen high-contrast acuity test. IOP was also measured by
the ophthalmic technicians, and the findings were reviewed
by the physicians. IOP was measured with pneumotonom-
eter. The ophthalmic technicians were not informed of the
purpose of the study or the assignment schedule. Anti-
glaucoma eye drops and/or acetazolamide were used when
an IOP of 22 mmHg or higher persisted for 3 days.
Statistical analysis
The visual acuity was converted to the logarithm of the
minimum angle of resolution (LogMAR), and the baseline
value was compared with those at 1 week, 1 month,
3 months, 6 months, and 1 year. The eyes were categorized
into the following three groups: (1) the improved group, in
which patients showed a 0.3 logMAR or greater improve-
ment of visual acuity at the final examination compared
with baseline, (2) the deteriorated group, in which patients
showed a 0.3 logMAR or worse deterioration of visual
acuity at the final examination compared with baseline, and
(3) the unchanged group, in which patients did not meet the
criteria of either the improved or the deteriorated group.
A Kaplan-Meier survival analysis was used to estimate
the probability of improved visual acuity with time after
surgery. The improvement or deterioration was analyzed by
the log rank test. The earliest time point after surgery at
which the events in each category were reported was
designated as the time point of each event.
We also estimated the multiple-adjusted odds ratio (OR)
andthe95%confidenceinterval(95%CI)bothforTAuseand
for the other variables, using a logistic regression model. The
parameters that were adjusted for included age, gender, and
disease diagnosis, which was categorized into the following
fivegroups:proliferativediabeticretinopathy(PDR),diabetic
macular edema (DME), rhegmatogenous retinal detachment
(RRD), retinal vein occlusion(RVO), andothers. A diagnosis
of PDR was used as a reference. Even when a single eye
received multiple additional surgeries, it was counted as one
eye. All statistical analyses were performed using SAS®
(Proprietary Software Release 8.2; SAS Institute Inc., Cary,
NC, USA). The differences in diagnosis or surgical interven-
tion between the two groups were compared using a two-
tailed Chi-squared test with the Yates’ correction. P values<
0.05 were considered statistically significant.
Results
Number of eyes
In total, 920 patients were initially registered for PPV during
this period. Among these, 146 eyes were not included in the
study because they did not meet the eligibility criteria or
because the patient declined to participate. In total, 774 eyes
were randomized, with 391 eyes (from 216 male and 175
female patients) assigned to the TA-assisted PPV group and
383 eyes (201 male and 182 female patients) assigned to the
conventional PPV group. The mean ages of the patients
were 63.5±12.1 years in the TA-assisted PPV group and
63.0±11.3 years in the conventional PPV group. In total, 19
eyes that were originally assigned to the conventional PPV
group received unplanned TA based on surgical judgment.
The 1-year post-operative follow-up was completed for a
total of 305 eyes in the TA-assisted PPV group (78.0%) and
295 eyes in the conventional PPV group (77.0%). The
overall follow-up rate was 77.5% (Fig. 1).
Diagnoses
The diagnoses for each group are shown in Table 1.I nb o t h
groups, PDR accounted for the largest number of cases,
followed by RRD. In both groups, the pattern at the 1-year
follow-up was similar to that at the baseline, and the
different diagnoses had significantly different distributions
within the two groups: the TA-assisted PPV group had a
relatively larger number of patients with DME (P=0.018 at
baseline, P=0.006 at 1-year follow-up) and a smaller number
of patients with epiretinal membrane (ERM) formation
(P=0.031 at baseline, P=0.008 at 1-year follow-up).
There were no significant differences between the two
groups in the usage of surgical methods, such as cataract
surgery (phacoemulsification P=0.724 and pars plana
lensectomy P=0.272), ILM peeling (P=0.075) and endo-
laser-photocoagulation (P=0.413), or in the use of post-
operative tamponade (sulfur hexafluoride gas P=0.810,
octa-fluorepropane gas P=0.756, room air P>0.999, and
silicone oil P=0.831) [13].
Visual acuity
The visual acuity in both groups improved over time. In the
TA-assisted PPV group, 322 eyes were categorized as
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categorized as deteriorated. In the conventional PPV group,
312 eyes were categorized as improved, 45 eyes were
categorized as unchanged, and 26 eyes were categorized as
deteriorated. The log-rank test revealed no significant
difference between the two groups regarding the improve-
ment (P=0.98) or deterioration (P=0.26) of visual acuity.
The logistic regression model also showed that the intra-
operative use of TA was not a significant factor for the
improvement of visual acuity (P=0.91) after adjusting for
age, gender, and diagnosis (Table 2). Neither gender (P=
0.54) nor age (P=0.31) was a significant factor for the
improvement of visual acuity. However, PDR diagnosis
was a significant factor for the improvement of visual
acuity compared with DME (OR=0.63, 95%CI=0.478–
0.817, P=0.0006; Table 2).
Table 1 Diseases of each group at baseline and 1 year after surgery
TA-assisted PPV Conventional PPV
Baseline 1 year baseline 1 year
N (%) N (%) N (%) N (%)
AMD 7 (1.8%) 3 (1.0%) 3 (0.8%) 3 (1.0%)
BRVO 50 (12.8%) 41 (13.4%) 37 (9.7%) 29 (9.8%)
CRVO 11 (2.8%) 9 (3.0%) 7 (1.8%) 6 (2.0%)
DME 67 (17.1%) 60 (19.7%) 42 (11.0%) 34 (11.5%)
ERM 24 (6.1%) 19 (6.2%) 41 (10.7%) 37 (12.5%)
Lens luxation 16 (4.1%) 11 (3.6%) 16 (4.2%) 12 (4.1%)
Macroaneurysm 10 (2.6%) 8 (2.6%) 9 (2.3%) 4 (1.4%)
PDR 113 (28.9%) 85 (27.9%) 131 (34.2%) 101 (34.2%)
RRD 80 (20.5%) 59 (19.3%) 77 (20.1%) 54 (18.3%)
VH 6 (1.5%) 6 (2.0%) 14 (3.7%) 11 (3.7%)
Others 7 (1.8%) 4 (1.3%) 6 (1.6%) 4 (1.4%)
total 383 (100%) 305 (100%) 391 (100%) 295 (100%)
TA; triamcinolone acetonide: PPV; pars plana vitrectomy: AMD; age-related macular degeneration: BRVO;branch retinal vein occlusion: CRVO:
central retinal vein occlusion: DME; diabetic macular edema: ERM; epiretinal membrane: PDR; proliferative diabetic retinopathy: RRD;
rhegmatogenous retinal detachment: VH; vitreous hemorrhage.
Fig. 1 Schematic diagram of
the study. TA: triamcinolone
acetonide, PPV: pars plana
vitrectomy
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Subgroup analysis
In terms of post-operative complications, there was not any
statisticallysignificantdifference.FibrousERMwasobserved
infiveeyes(1.4%)intheconventionalPPVgroup,butinonly
one eye (0.3%) in the TA-assisted PPV group. A subgroup
analysis showed that this difference was not significant (P=
0.10). Among the other complications, an IOP increase was
found more frequently in the TA-assisted PPV group (23
eyes, 5.9%) than in the conventional PPV group (13 eyes,
3.4%), although this difference was not statistically signifi-
cant (P=0.10). There were no significant differences in the
other complications between the two groups (Table 3).
Additional surgery
Although the filtering surgery was more performed in TA-
assisted PPV and the removal of vitreous hemorrhage was
more performed in conventional PPV, there was not any
statistically significant difference between the two groups
with respect to causes of additional surgery after PPV. In
the TA-assisted PPV group, 22 surgeries were performed
(excluding filtering surgery). The most common reasons for
additional surgery were removal of silicone oil (11 eyes),
followed by retinal detachment (eight eyes), VH (six eyes),
and others (seven eyes). In the conventional PPV group, 26
surgeries were performed (excluding filtering surgery). The
most common reasons were VH (12 eyes), followed by
retinal detachment (nine eyes), removal of silicone oil
(seven eyes), and others (six eyes). Although there was a
tendency for VH to be less common in TA-assisted PPV
eyes, no significant difference was found in comparison to
conventional PPV (P=0.13; Table 4). Filtering surgery was
more frequently performed in the TA-assisted PPV group
(15 cases, 3.8%) than the conventional PPV group (seven
cases, 1.8%), although this difference was not significant
(P=0.10). Ten eyes received multiple additional surgeries in
TA-assisted PPV group and seven eyes in conventional
PPV group.
The survival curve produced by the log-rank test showed
that the incidence of additional surgery was not significant-
ly different between the two groups (P=0.45). The logistic
regression test also showed that the use of TA was not a
significant factor for additional surgery after adjustments
for gender, age, and diagnosis. However, a diagnosis of
PDR was a significant factor for additional surgery in
Table 3 Post-operative complications in each group
TA-assisted PPV (total 391 eyes): n (%) Conventional PPV (total 383 eyes): n (%) P-value*
After cataract 18 (4.6%) 17 (4.4%) 0.91
Macular pucker 23 (5.9%) 22 (5.7%) 0.93
IOP increase 23 (5.9%) 13 (3.4%) 0.10
Retinal detachment 9 (2.3%) 9 (2.3%) 0.96
Vitreous hemorrhage 22 (5.6%) 29 (7.8%) 0.28
Fibrous membrane 1 (0.3%) 5 (1.4%) 0.10
Iris synechiae 6 (1.5%) 4 (1.0%) 0.55
Others 8 (2.0%) 12 (3.1%) 0.34
TA; triamcinolone acetonide: PPV; pars plana vitrectomy: PPL; pas plana lensectomy: IOP; intraocular pressure: * Chi-square test with the Yates’
correction.
Table 2 Factors affecting improvement of visual acuity
Variable (no. of improved eyes/total eyes) Odds ratio (95%CI) P-value
TA-assisted PPV (322/391) vs conventional PPV (312/383) 1.10 (0.860–1.183) 0.91
Age 1.00 (0.991–1.005) 0.54
Gender (male vs female) 0.92 (0.785–1.080) 0.31
Diseases
RD vs PDR 1.04 (0.834–1.340) 0.71
DME vs PDR 0.63 (0.478–0.817) 0.0006*
RVO vs PDR 1.21 (0.938–1.561) 0.14
ERM vs PDR 0.78 (0.568–1.061) 0.11
Others vs PDR 1.21 (0.924–1.579) 0.17
CI; confidence interval: TA; triamcinolone acetonide: PPV; pars plana vitrectomy: RVO; branch retinal vein occlusion + central retinal vein
occlusion: DME; diabetic macular edema: ERM; epiretinal membrane: PDR; proliferative diabetic retinopathy: RRD; rhegmatogenous retinal
detachment. * statistically significant
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ERM (P=0.02; Table 5). None of the variables were related
to the requirement for filtering surgery (Table 6).
Serious adverse events
None of the serious adverse events related to surgery
defined in this study (such as retinal degeneration,
endophthalmitis, an unexplained decrease in visual acuity,
or optic-disc atrophy) were observed in either group during
the 1-year follow-up.
Discussion
The first report on this study showed that the intra-operative
use of TA significantly decreased the incidence of intra-
operative complications associated with PPV,and no adverse
events related to surgery were found over a 3-month
observation period [13]. A decreased incidence of intra-
operative complications is beneficial; however, the critical
issue is whether the surgery improves the patients’ vision.
We therefore followed up the visual acuity, which is a
crucial factor influencing vision, for 1 year after surgery.
Our results revealed no significant difference in visual
acuity between the TA-assisted PPV group and the
conventional PPV group after 1 year. As described in the
earlier report, which analyzed data from the same eyes,
intra-operative retinal breaks and retinal detachment were
significantly less frequent in the TA-assisted PPV group
than in the conventional PPV group. Nonetheless, the
decreased incidence of intra-operative complications did
not significantly affect the visual acuity after 1 year. This
finding can be explained by the following facts. First,
surgical skill is the most important factor for surgical
success. As all of the operations in this study were
performed by qualified and experienced surgeons, the
intra-operative complications were managed so as not to
cause serious post-operative complications. Thus, the
influence of intra-operative complications on visual acuity
might have been minimal. Second, a patient’s vision after
vitrectomy might be more strongly affected by a disease
diagnosis than by intra-operative complications. Indeed,
eyes with PDR were significantly more likely to show
improved visual acuity compared with baseline than eyes
with DME in the current study. As our present case series
included various diseases, the impact of intra-operative
complications on post-operative visual acuity might have
been masked by another strong factor, such as disease
diagnosis, even after adjustments. Third, the eyes in the
Table 5 Factors affecting additional surgery
Variable (no. of additional surgery/total) Odds ratio (95%CI) P-value
TA-assisted PPV (37/391) vs conventional PPV (32/383) 1.23 (0.797–1.911) 0.35
Age 0.97 (0.950–0.984) 0.0001*
Gender (male vs female) 1.15 (0.733–1.797) 0.55
Diseases
RD vs PDR 0.60 (0.345–1.029) 0.06
DME vs PDR 0.29 (0.122–0.681) 0.005*
RVO vs PDR 0.23 (0.084–0.657) 0.006*
ERM vs PDR 0.087 (0.012–0.631) 0.02*
Others vs PDR 0.64 (0.299–1.374) 0.25
CI; confidence interval: RVO; branch retinal vein occlusion + central retinal vein occlusion: DME; diabetic macular edema: ERM; epiretinal
membrane: PDR; proliferative diabetic retinopathy: RRD; rhegmatogenous retinal detachment. * statistically significant
Table 4 Causes of additional surgery after PPV
TA-assisted PPV (total 391 eyes): n (%) Conventional PPV (total 383 eyes) : n (%) P-value*
Silicone removal 11 (2.8%) 7 (1.8%) 0.36
Retinal detachment 8 (2.0%) 9 (2.3%) 0.77
Vitreous hemorrhage 6 (1.5%) 12 (3.1%) 0.14
Filtering surgery 15 (3.8%) 7 (1.8%) 0.10
Others 7 (1.8%) 6 (1.6%) 0.81
Total 37 (9.5%)
✝ 32 (8.6%)
✝✝ 0.68
TA; triamcinolone acetonide: PPV; pars plana vitrectomy: * Chi-square test with the Yates’ correction:
✝ Ten eyes received multiple additional
surgeries:
✝✝ Seven eyes received multiple additional surgeries.
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intra-operative retinal breaks, based on the hypothesis that
the intra-operative use of TA might decrease their incidence
from 15% to 8% [13]. Thus, the sample size might not have
been large enough to detect the superiority or inferiority of
TA-assisted PPV. For example, in order to detect the
difference of post-operative improvement of vision in TA-
assisted PPVand conventional PPV based upon the present
results, approximately 29,315 cases in each group are
necessary with a power of 0.05 and 1-β of 0.8. However,
considering the relative stability of the visual acuity
observed here, we are confident that the intra-operative
use of TA does not have a positive or negative effect on
postoperative visual acuity for 1 year.
Additional surgeries carry associated risks and can be
costly; they are thus important when justifying the intra-
operative use of TA in PPV. The incidence of additional
surgery after vitrectomy was found to be equivalent using
both methods. Considering the IOP increase after surgery,
the opportunity to use anti-glaucoma eye drops was high in
the TA-assisted PPV group [13], and the number of filtering
surgeries performed during 1 year after TA-assisted PPV
was also high; however, the incidence of additional surgeries
was not statistically different between the groups. Several
previous reports showed that intravitreous TA injection
required filtering surgery, and its frequency was less than
1% of all treated eyes [18, 19]. In contrast to intravitreous
TA injection, most of the TA was removed from the eye at
the end of the surgery. Thus, it was plausible that the
necessity of filtering surgery in TA-assisted PPV was not
significant. The other causes of additional surgery occurred
at similar frequencies, and there were no significant
differences between the groups. A diagnosis of PDR was
a significant factor for the requirement for additional
surgery, as it was for the improvement of visual acuity.
Furthermore, in our earlier report on the 3-month follow-up
study, a diagnosis of PDR was found to be a significant risk
factor for the occurrence of intra-operative complications.
PDR eyes thus appear to have several poor prognostic
factors, consistent with the present results.
With regard to the post-operative complications, pre-
retinal fibrosis appeared to be less common in the TA-
assisted PPV group than in the conventional PPV group,
although this was not statistically significant. This advan-
tage of TA-assisted PPV has been described in previous
reports [3, 5–9]. The intra-operative use of TA visualizes
the posterior hyaloid clearly, which facilitates its removal
[6, 7]; as the residual posterior hyaloid can act as a scaffold
for pre-retinal fibrous-membrane formation, its removal
could reduce the incidence of post-operative pre-retinal
fibrosis [5–7]. In the current study group, the removal of
the residual posterior hyaloid was carried out according to
the surgeons’ preference—some surgeons removed it
completely, while others did not. This might have obscured
any potential advantage of the intra-operative use of TA in
inhibiting post-operative pre-retinal fibrosis.
There were clear limitations to our analysis. The number
of cases in each study group was primarily chosen to allow
the detection of intra-operative complications; thus, the
significance of the intra-operative use of TA might only
become clear when studying larger numbers of patients. In
addition, the sample size was too small to detect the risk of
endophthalmitis. The incidence of endophthalmitis related
to PPV was 0.046% in the conventional PPV group and
0.053% in the TA-assisted PPV group [20, 21]. An analysis
of a greater number of cases will thus be necessary to
evaluate the risk of endophthalmitis related to TA-assisted
PPV. However, the present sample size was large enough to
detect several factors that affected post-operative visual
acuity or the need for additional surgery. Another limitation
was that the post-operative visual acuity was strongly
influenced by the diagnosis of disease. Eyes with simple
VH clearly had a greater chance of surgery improving
vision above the baseline level than did eyes with com-
Table 6 Factors affecting filtering surgery
Variable (no. of filtering surgery/total) Odds ratio (95%CI) P-value
TA-assisted PPV (12/391) vs conventional PPV (5/383) 1.74 (0.708–4.265) 0.23
Age 0.98 (0.941–1.018) 0.28
Gender (male vs female) 1.81 (0.696–4.728) 0.22
Diseases
RRD vs PDR – 0.99
DME vs PDR – 0.99
RVO vs PDR – 0.99
ERM vs PDR – 0.99
Others vs PDR 0.83 (0.266–2.573) 0.74
CI; confidence interval: TA; triamcinlone acetonide: PPV; pars plana vitrectomy: RVO; branch retinal vein occlusion + central retinal vein
occlusion: DME; diabetic macular edema: ERM; epiretinal membrane: PDR; proliferative diabetic retinopathy: RRD; rhegmatogenous retinal
detachment
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operative use of TA on visual acuity more precisely, we are
currently performing a study on eyes with the same disease
diagnosis. Furthermore, the subgroup of DME or ERM in
each group was not completely matched. The interpretation
of the results should be done carefully. Additionally,
caution must be applied when making generalizations on
the basis of our current results, and their application to
clinical practice must be undertaken with care. Other
factors, such as invasiveness and cost, are also important
in seeking justification for this treatment. The success of
surgery depends upon various factors, and surgical skill is
critical. When considering the likelihood of retinal breaks
and their recovery without damaging vision, comparisons
of the hazard ratios of TA-assisted PPV and conventional
PPV would be valid only if made by individuals who
qualify as PPV specialists.
In summary, the intra-operative use of TA in PPV did
not affect visual acuity over 1 year. As negative or adverse
events were not observed in this case series, a more detailed
study is warranted to establish the value of TA in PPV.
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